# Medison Pharma

> Medison Pharma is a VC fund in Israelândia backing Health Care and Therapeutics. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Israelândia, Brazil
- Total investments: 2
- Last investment: Mar 2020
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/medison-pharma-ltd/
- Website: http://www.medison.co.il/
- Facebook: https://www.facebook.com/MedisonPharma.Israel/

Medison Pharma is a VC fund in Israelândia focused on Health Care and Therapeutics. Medison is a uniquely qualified to provide the complete spectrum of integrated services for international companies looking to enter.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 1 | 50% |
| Therapeutics | 1 | 50% |
| Biotechnology | 1 | 50% |
| Pharmaceutical | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 50% |
| Series C | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Keros Therapeutics | Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with a high unmet medical need. Keros is a leader in understanding the role of the Transforming Growth Factor-Beta, or TGF-ß, family of proteins,which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros' lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros' lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros' third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. | $56M | Series C | Mar 04, 2020 |  |
| Keros Therapeutics | Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with a high unmet medical need. Keros is a leader in understanding the role of the Transforming Growth Factor-Beta, or TGF-ß, family of proteins,which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros' lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros' lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros' third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. | $23M | Series B | Jan 08, 2019 |  |

2 of 2 investments shown.

## Co-investors
- [Arkin Bio Ventures](https://shizune.co/investors/profile/arkin-bio-ventures) — VC Fund, 2 deals together
- [Global health sciences venture fund](https://shizune.co/investors/profile/global-health-sciences-venture-fund) — VC Fund, 2 deals together
- [Partners Innovation Fund](https://shizune.co/investors/profile/partners-innovation-fund) — VC Fund, 2 deals together
- [Pontifax](https://shizune.co/investors/profile/pontifax) — VC Fund, 2 deals together
- [Cowen Healthcare Investments](https://shizune.co/investors/profile/cowen-healthcare-investments) — VC Fund, 1 deal together
- [Foresite Capital](https://shizune.co/investors/profile/foresite-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Medison Pharma invest in?

Medison Pharma invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series B and Series C stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Medison Pharma last invest?

The most recent investment recorded for Medison Pharma closed in Mar 2020. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co